This review is an evidence- and experience-based approach to the management of SLE, particularly its kidney manifestations. Specific protocols in substantial clinical detail are provided for management and monitoring, according to the severity of the SLE manifestations. The protocols are adapted from those used in a major SLE trial. The adaptations are based on subsequent extensive clinical use of these protocols. Also described is the concomitant use of cardio- and kidney-protective therapies to optimize patient outcomes.

Keywords:
Systemic lupus erythematosus nephritis, Systemic lupus erythematosus treatment
1.
Hebert LA: Glomerular Diseases. The American College of Physicians Nephrology Medical Knowledge Self Assessment Program (MKSAP), 1998, pp 18–24.
2.
Hebert LA, Wilmer WA, Falkenhain ME, et al: Renoprotection: One or many therapies? Kidney Int 2001;59:1484–1490.
3.
Lewis EJ, Hunsicker Lg, Lan S-P, et al: A controlled trial of plasmapheresis therapy in severe lupus nephritis. N Engl J Med 1992;326:1373–1379.
4.
Hebert LA, Middendorf DF, Dillon JJ, Lewis EJ, Peter JB: Relationship between appearance of urinary red cell/white cell casts and the onset of renal relapse in systemic lupus erythematosus. Am K Kidney Dis 1995;26:432–438.
5.
Levey AS, Lan S-P, Corwin HL, et al: Progression and remission of renal disease in the Lupus Nephritis Collaborative Study: Results of treatment with prednisone and short-term oral cyclophosphamide. Ann Intern Med 1992;116:114–123.
6.
Hill GS, Delahousse M, Nochy D, et al: Predictive power of the second renal biopsy in lupus nephritis: Significance of macropahges. Kidney Int 2001;59:304–316.
7.
Balow JE, Boumpas DT, Fessler BJ, Austin HA III: Management of lupus nephritis. Kidney Int 1996;49:S88–S92.
8.
Illei GG, Austin HA, Crane M, et al: Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001;135:248–257.
9.
Chan TM, Li FK, Tang CSO, et al: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000;343:1156–1162.
10.
Buyon JP, Wallace DJ: The endocrine system, use of exogenous estsrogens, and the urogenital tract; in Wallace DJ, Hahn BH (eds): Dubois’ Lupus Erythematosus, ed 5. Baltimore, Williams & Wilkins, 1997, chap 44, pp 817–834.
11.
Blumenfeld Z, Shapiro D, Shteinberg M, Avivi I, Nahir M: Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 2000;9:401–405.
12.
Masala A, Faedda R, Alagna S, et al: Use of testosterone to prevent cyclophosphamide-induced azoospermia. Ann Intern Med 1997;126:292–295.
13.
Hay EM, Bacon PA, Gordon C, et al: The BILAG index: A reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993;86:447–458.
14.
Balow JE, Austin HA III: Progress in the treatment of proliferative lupus nephritis. Curr Opin Nephrol Hypertens 2000;9:107–115.
15.
Traynor AE, Schroeder J, Rosa RM, et al: Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: A phase I study. Lancet 2000;356:701–707.
© 2003 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.